Natdac

Uses
Natdac (Daclatasvir Dihydrochloride) is indicated in the treatment of chronic hepatitis C virus (HCV) with genotype 1 or genotype 3 infection. Daclatasvir is never prescribed alone. It will be prescribed with sofosbuvir, or with sofosbuvir and ribavirin depending on the genotype and patient medical history.

Dosage and Administration
In most cases, the prescribed dosage will be 60mg (one tablet) daily. Swallowed each tablet whole with a glass of water. Natdac can be taken with or without food.

Treatment for hepatitis C will usually last for a period of 12 weeks.

Natdac must always be taken with Sofosbuvir, and in some cases it will also need to be taken with Ribavarin. Natdac and sofosbuvir will be prescribed in patients without cirrhosis, and in patients with genotype 1 infection and compensated (Child-Pugh A) cirrhosis. Natdac, sofosbuvir and ribavirin will be prescribed in patients with decompensated (Child-Pugh B or C) cirrhosis, patients with genotype 3 infection and compensated (Child-Pugh A) cirrhosis and any post-transplant patients.

Side effects
Natdac (Daclatasvir Dihydrochloride) can cause some unwanted side effects. Common side effects of treatment with daclatasvir and sofosbuvir include headache, fatigue, nausea and diarrhea. Common side effects of treatment with daclatasvir, sofosbuvir and ribavirin include headache, fatigue, nausea, diarrhea, anemia, rash, insomnia, dizziness and somnolence.

Contact your doctor if any of these become troublesome to you, or if you develop any signs of allergy.

Precautions
Natdac (Daclatasvir Dihydrochloride) and Sofosbuvir when taken with Amiodarone can result in serious symptomatic bradycardia. This risk is higher in patients who are also taking beta-blockers or patients with heart problems or liver disease.

Tell your doctor if you are taking any of the following before beginning treatment: phenytoin, carbamazepine, rifampin, and St. John’s wort.

The following medicines are known to interact with Daclatasvir:

• Protease inhibitors (atazanavir with ritonavir, indinavir, nelfinavir, saquinavir)
• Other antiretrovirals (eg. atazanavir/cobicistat, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate)
• Non-nucleoside reverse transcriptase inhibitors (efavirenzb, etravirine, nevirapine)
• Strong CYP3A inhibitors (eg. clarithromycin, itraconazole, ketoconazole, nefazodone, posaconazole, telithromycin, voriconazole)
• Moderate CYP3A inducers (eg. bosentan, dexamethasone, modafinil, nafcillin, rifapentine)
• Anticoagulants (dabigatran etexilate mesylate)
• Cardiovascular agents (Amiodarone, Digoxin)
• HMG-CoA reductase inhibitors (Atorvastatin, Fluvastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin)
• Narcotic Analgesics (buprenorphine, buprenorphine/naloxone)

Daclatasvir may increase the risk of birth defects and miscarriage. Men whose partners are pregnant, pregnant women, women who are trying to become pregnant, and men whose partners are trying to become pregnant shoulde exercise care and check with their doctor before using Natdac (Daclatasvir Dihydrochloride).

Daclatasvir may not be safe to use in patients under 18 years old.